Denali Therapeutics Inc. (DNLI)
| Market Cap | 3.10B +55.8% |
| Revenue (ttm) | n/a |
| Net Income | -508.02M |
| EPS | -2.88 |
| Shares Out | 158.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,859,733 |
| Open | 19.94 |
| Previous Close | 20.14 |
| Day's Range | 19.24 - 19.94 |
| 52-Week Range | 12.58 - 23.77 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 34.55 (+73.82%) |
| Earnings Date | May 7, 2026 |
About DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzym... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for DNLI stock is "Buy." The 12-month stock price target is $34.55, which is an increase of 73.82% from the latest price.
News
Denali Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
AVLAYAH’s approval marks a breakthrough in blood-brain barrier drug delivery, with rapid launch uptake and a robust pipeline targeting neurodegenerative and lysosomal diseases. Upcoming data from Sanfilippo, FTD, and Alzheimer’s programs, plus ongoing COMPASS and BEACON studies, are expected to drive further growth and label expansion.
Denali Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with the election of three directors, ratification of Ernst & Young as auditors for 2026, and advisory approval of executive compensation. All proposals passed, with final results to be filed in a Form 8-K.
Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Denali Therapeutics (DNLI) to $35 from $40 and keeps an Overweight rating on the shares. The Phase 2b LUMA study failed to…
Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Denali Therapeutics (DNLI) to $31 from $35 and keeps a Buy rating on the shares.
Denali Therapeutics trading resumes
18:35 EDT Denali Therapeutics (DNLI) trading resumes
Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an investigational small molecule inhibitor of LRRK2, in individuals with early-...
Denali Therapeutics trading halted, news pending
17:55 EDT Denali Therapeutics (DNLI) trading halted, news pending
Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Denali Therapeutics (DNLI) to $40 from $42 and keeps an Overweight rating on the shares.
Denali Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
AVLAYAH’s launch for Hunter syndrome is progressing well, with strong early engagement and a clear path to expand the label to adults pending COMPASS study results. The pipeline includes promising programs for Sanfilippo, Pompe, Parkinson’s, and frontotemporal dementia, leveraging a robust platform and global partnerships.
Denali Therapeutics Slides: Corporate presentation
Denali Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Denali Therapeutics price target lowered to $23 from $25 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on Denali Therapeutics (DNLI) to $23 from $25 and keeps an Outperform rating on the shares. The firm notes the Avlayah…
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2026, and provided business...
Denali Therapeutics Quarterly report: Q1 2026
Denali Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Denali Therapeutics Earnings release: Q1 2026
Denali Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Denali Therapeutics Proxy statement: Proxy filing
Denali Therapeutics filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Denali Therapeutics Proxy statement: Proxy filing
Denali Therapeutics filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Denali Therapeutics price target raised to $34 from $32 at Baird
Baird raised the firm’s price target on Denali Therapeutics (DNLI) to $34 from $32 and keeps an Outperform rating on the shares. The firm updated its model following the return…
Denali Therapeutics price target raised to $39 from $38 at BTIG
BTIG raised the firm’s price target on Denali Therapeutics (DNLI) to $39 from $38 and keeps a Buy rating on the shares as the company regains full rights to investigational…
Denali Therapeutics regains full rights to DNL593
Denali Therapeutics (DNLI) announced that it has received notification from Takeda (TAK) of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commerc...
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it has received notification from Takeda of its decision to terminate the c...
Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Denali Therapeutics (DNLI) to $35 from $26 and keeps a Buy rating on the shares. The firm says the approval of Avlayah…
Denali Therapeutics price target raised to $42 from $32 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Denali Therapeutics (DNLI) to $42 from $32 and keeps a Buy rating on the shares after the FDA granted accelerated approval for…
Denali Therapeutics price target raised to $42 from $40 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Denali Therapeutics (DNLI) to $42 from $40 and keeps an Overweight rating on the shares after the company received FDA accelerated approval…
Denali Therapeutics price target raised to $31 from $29 at BofA
BofA raised the firm’s price target on Denali Therapeutics (DNLI) to $31 from $29 and keeps a Buy rating on the shares after the company announced the accelerated approval of…
Denali Therapeutics price target raised to $41 from $34 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Denali Therapeutics (DNLI) to $41 from $34 and keeps a Buy rating on the shares following Avlayah’s approval for the…